nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexamethasone—ANXA1—esophageal cancer	0.182	0.331	CbGaD
Dexamethasone—CYP4A11—Cisplatin—esophageal cancer	0.0878	0.33	CbGbCtD
Dexamethasone—NOS2—esophageal cancer	0.0851	0.155	CbGaD
Dexamethasone—CYP1B1—esophageal cancer	0.0724	0.132	CbGaD
Dexamethasone—ABCC2—esophageal cancer	0.0565	0.103	CbGaD
Dexamethasone—CYP2A6—esophageal cancer	0.0558	0.101	CbGaD
Dexamethasone—CYP19A1—esophageal cancer	0.0531	0.0966	CbGaD
Dexamethasone—PTGS2—esophageal cancer	0.0244	0.0444	CbGaD
Dexamethasone—ABCC2—Carboplatin—esophageal cancer	0.0224	0.0842	CbGbCtD
Dexamethasone—ABCB1—esophageal cancer	0.0208	0.0378	CbGaD
Dexamethasone—ABCG2—Carboplatin—esophageal cancer	0.0203	0.0761	CbGbCtD
Dexamethasone—ABCC2—Cisplatin—esophageal cancer	0.0192	0.072	CbGbCtD
Dexamethasone—PTGS2—Cisplatin—esophageal cancer	0.0189	0.0711	CbGbCtD
Dexamethasone—ABCG2—Cisplatin—esophageal cancer	0.0173	0.0651	CbGbCtD
Dexamethasone—SLCO1A2—Methotrexate—esophageal cancer	0.015	0.0564	CbGbCtD
Dexamethasone—CYP2C9—Capecitabine—esophageal cancer	0.0128	0.048	CbGbCtD
Dexamethasone—ABCC2—Methotrexate—esophageal cancer	0.0124	0.0467	CbGbCtD
Dexamethasone—CYP2B6—Cisplatin—esophageal cancer	0.0122	0.0458	CbGbCtD
Dexamethasone—ABCG2—Methotrexate—esophageal cancer	0.0113	0.0422	CbGbCtD
Dexamethasone—CYP2C9—Cisplatin—esophageal cancer	0.00644	0.0242	CbGbCtD
Dexamethasone—ABCB1—Cisplatin—esophageal cancer	0.00625	0.0235	CbGbCtD
Dexamethasone—ABCB1—Methotrexate—esophageal cancer	0.00406	0.0152	CbGbCtD
Dexamethasone—Skin depigmentation—Methotrexate—esophageal cancer	0.00225	0.0401	CcSEcCtD
Dexamethasone—PLA2G1B—exocrine gland—esophageal cancer	0.00224	0.0801	CbGeAlD
Dexamethasone—Mass—Capecitabine—esophageal cancer	0.00174	0.031	CcSEcCtD
Dexamethasone—ANXA1—exocrine gland—esophageal cancer	0.00171	0.0613	CbGeAlD
Dexamethasone—Aseptic necrosis—Methotrexate—esophageal cancer	0.00163	0.029	CcSEcCtD
Dexamethasone—Paraplegia—Methotrexate—esophageal cancer	0.00139	0.0247	CcSEcCtD
Dexamethasone—Oesophageal candidiasis—Capecitabine—esophageal cancer	0.00138	0.0246	CcSEcCtD
Dexamethasone—Extravasation—Carboplatin—esophageal cancer	0.00134	0.0238	CcSEcCtD
Dexamethasone—Personality change—Capecitabine—esophageal cancer	0.00132	0.0234	CcSEcCtD
Dexamethasone—Diplegia—Methotrexate—esophageal cancer	0.00129	0.023	CcSEcCtD
Dexamethasone—Glucose tolerance impaired—Cisplatin—esophageal cancer	0.00127	0.0226	CcSEcCtD
Dexamethasone—Monoplegia—Methotrexate—esophageal cancer	0.00121	0.0216	CcSEcCtD
Dexamethasone—ANXA1—neck—esophageal cancer	0.0011	0.0392	CbGeAlD
Dexamethasone—Papilloedema—Cisplatin—esophageal cancer	0.00108	0.0192	CcSEcCtD
Dexamethasone—Arachnoiditis—Methotrexate—esophageal cancer	0.00103	0.0183	CcSEcCtD
Dexamethasone—PLA2G1B—epithelium—esophageal cancer	0.000975	0.0349	CbGeAlD
Dexamethasone—CYP4A11—digestive system—esophageal cancer	0.000896	0.032	CbGeAlD
Dexamethasone—NR0B1—lung—esophageal cancer	0.00087	0.0311	CbGeAlD
Dexamethasone—Amcinonide—ANXA1—esophageal cancer	0.00082	0.363	CrCbGaD
Dexamethasone—Telangiectasia—Methotrexate—esophageal cancer	0.000797	0.0142	CcSEcCtD
Dexamethasone—ANXA1—epithelium—esophageal cancer	0.000746	0.0267	CbGeAlD
Dexamethasone—PLA2G1B—digestive system—esophageal cancer	0.000742	0.0265	CbGeAlD
Dexamethasone—ANXA1—bronchus—esophageal cancer	0.000735	0.0262	CbGeAlD
Dexamethasone—Cognitive impairment—Methotrexate—esophageal cancer	0.000719	0.0128	CcSEcCtD
Dexamethasone—ANXA1—smooth muscle tissue—esophageal cancer	0.000719	0.0257	CbGeAlD
Dexamethasone—Oesophageal ulcer—Capecitabine—esophageal cancer	0.000691	0.0123	CcSEcCtD
Dexamethasone—ANXA1—trachea—esophageal cancer	0.00066	0.0236	CbGeAlD
Dexamethasone—PLA2G1B—lung—esophageal cancer	0.00062	0.0221	CbGeAlD
Dexamethasone—Blindness—Cisplatin—esophageal cancer	0.000618	0.011	CcSEcCtD
Dexamethasone—ABCB11—digestive system—esophageal cancer	0.000577	0.0206	CbGeAlD
Dexamethasone—ANXA1—digestive system—esophageal cancer	0.000567	0.0203	CbGeAlD
Dexamethasone—Diabetic—Methotrexate—esophageal cancer	0.000562	0.01	CcSEcCtD
Dexamethasone—Optic neuritis—Cisplatin—esophageal cancer	0.000556	0.0099	CcSEcCtD
Dexamethasone—Osteonecrosis—Methotrexate—esophageal cancer	0.000504	0.00897	CcSEcCtD
Dexamethasone—NR3C2—bronchus—esophageal cancer	0.000476	0.017	CbGeAlD
Dexamethasone—ANXA1—lung—esophageal cancer	0.000474	0.0169	CbGeAlD
Dexamethasone—Opportunistic infection—Methotrexate—esophageal cancer	0.000466	0.0083	CcSEcCtD
Dexamethasone—NR3C2—smooth muscle tissue—esophageal cancer	0.000465	0.0166	CbGeAlD
Dexamethasone—PGR—epithelium—esophageal cancer	0.000449	0.016	CbGeAlD
Dexamethasone—Leukoderma—Methotrexate—esophageal cancer	0.000441	0.00786	CcSEcCtD
Dexamethasone—Necrosis—Cisplatin—esophageal cancer	0.000436	0.00776	CcSEcCtD
Dexamethasone—Cognitive disorder—Methotrexate—esophageal cancer	0.000434	0.00773	CcSEcCtD
Dexamethasone—Impaired healing—Methotrexate—esophageal cancer	0.000434	0.00773	CcSEcCtD
Dexamethasone—Hirsutism—Capecitabine—esophageal cancer	0.000434	0.00773	CcSEcCtD
Dexamethasone—PGR—smooth muscle tissue—esophageal cancer	0.000433	0.0155	CbGeAlD
Dexamethasone—Abscess—Cisplatin—esophageal cancer	0.000432	0.0077	CcSEcCtD
Dexamethasone—NR3C2—trachea—esophageal cancer	0.000427	0.0153	CbGeAlD
Dexamethasone—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.000424	0.00755	CcSEcCtD
Dexamethasone—Visual acuity reduced—Capecitabine—esophageal cancer	0.000424	0.00755	CcSEcCtD
Dexamethasone—Infection—Carboplatin—esophageal cancer	0.000413	0.00736	CcSEcCtD
Dexamethasone—Embolism—Capecitabine—esophageal cancer	0.000393	0.007	CcSEcCtD
Dexamethasone—Extravasation—Cisplatin—esophageal cancer	0.000392	0.00698	CcSEcCtD
Dexamethasone—Keratitis—Capecitabine—esophageal cancer	0.000389	0.00692	CcSEcCtD
Dexamethasone—NR3C1—neck—esophageal cancer	0.000381	0.0136	CbGeAlD
Dexamethasone—NR3C2—digestive system—esophageal cancer	0.000367	0.0131	CbGeAlD
Dexamethasone—CYP1B1—smooth muscle tissue—esophageal cancer	0.000364	0.013	CbGeAlD
Dexamethasone—Ulcer—Cisplatin—esophageal cancer	0.000362	0.00644	CcSEcCtD
Dexamethasone—Hepatomegaly—Capecitabine—esophageal cancer	0.000356	0.00634	CcSEcCtD
Dexamethasone—Pain—Carboplatin—esophageal cancer	0.000356	0.00634	CcSEcCtD
Dexamethasone—Blister—Capecitabine—esophageal cancer	0.00035	0.00623	CcSEcCtD
Dexamethasone—Hydrocortisone—ANXA1—esophageal cancer	0.000346	0.153	CrCbGaD
Dexamethasone—Hiccups—Cisplatin—esophageal cancer	0.000342	0.00609	CcSEcCtD
Dexamethasone—Osteoporosis—Methotrexate—esophageal cancer	0.000335	0.00596	CcSEcCtD
Dexamethasone—Testolactone—CYP19A1—esophageal cancer	0.00033	0.146	CrCbGaD
Dexamethasone—Rash erythematous—Capecitabine—esophageal cancer	0.000329	0.00586	CcSEcCtD
Dexamethasone—Body temperature increased—Carboplatin—esophageal cancer	0.000329	0.00586	CcSEcCtD
Dexamethasone—CYP2A6—lung—esophageal cancer	0.000327	0.0117	CbGeAlD
Dexamethasone—Skin exfoliation—Cisplatin—esophageal cancer	0.000327	0.00582	CcSEcCtD
Dexamethasone—Fungal infection—Capecitabine—esophageal cancer	0.000327	0.00582	CcSEcCtD
Dexamethasone—Fluid retention—Cisplatin—esophageal cancer	0.000325	0.00578	CcSEcCtD
Dexamethasone—ANXA1—lymph node—esophageal cancer	0.000324	0.0116	CbGeAlD
Dexamethasone—Fracture—Methotrexate—esophageal cancer	0.000323	0.00575	CcSEcCtD
Dexamethasone—Multiple fractures—Methotrexate—esophageal cancer	0.000323	0.00575	CcSEcCtD
Dexamethasone—Neuropathy—Cisplatin—esophageal cancer	0.000321	0.00572	CcSEcCtD
Dexamethasone—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000316	0.00562	CcSEcCtD
Dexamethasone—SLCO1A2—digestive system—esophageal cancer	0.000315	0.0113	CbGeAlD
Dexamethasone—Tingling sensation—Capecitabine—esophageal cancer	0.000314	0.00559	CcSEcCtD
Dexamethasone—NR3C2—lung—esophageal cancer	0.000307	0.011	CbGeAlD
Dexamethasone—Petechiae—Capecitabine—esophageal cancer	0.000306	0.00546	CcSEcCtD
Dexamethasone—Folliculitis—Methotrexate—esophageal cancer	0.000299	0.00532	CcSEcCtD
Dexamethasone—ABCC2—digestive system—esophageal cancer	0.000293	0.0105	CbGeAlD
Dexamethasone—Embolism—Methotrexate—esophageal cancer	0.000292	0.00521	CcSEcCtD
Dexamethasone—CYP17A1—lymph node—esophageal cancer	0.000291	0.0104	CbGeAlD
Dexamethasone—Contusion—Capecitabine—esophageal cancer	0.000289	0.00515	CcSEcCtD
Dexamethasone—CYP1B1—digestive system—esophageal cancer	0.000287	0.0103	CbGeAlD
Dexamethasone—PGR—lung—esophageal cancer	0.000285	0.0102	CbGeAlD
Dexamethasone—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000274	0.00488	CcSEcCtD
Dexamethasone—Herpes simplex—Capecitabine—esophageal cancer	0.000274	0.00487	CcSEcCtD
Dexamethasone—CYP11A1—lymph node—esophageal cancer	0.00027	0.00966	CbGeAlD
Dexamethasone—CYP1A1—epithelium—esophageal cancer	0.000267	0.00954	CbGeAlD
Dexamethasone—Ulcer—Capecitabine—esophageal cancer	0.000267	0.00475	CcSEcCtD
Dexamethasone—Cataract—Capecitabine—esophageal cancer	0.000265	0.00472	CcSEcCtD
Dexamethasone—SLCO1A2—lung—esophageal cancer	0.000263	0.0094	CbGeAlD
Dexamethasone—CYP1A1—bronchus—esophageal cancer	0.000263	0.0094	CbGeAlD
Dexamethasone—NR3C1—epithelium—esophageal cancer	0.000259	0.00926	CbGeAlD
Dexamethasone—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000257	0.00457	CcSEcCtD
Dexamethasone—CYP2B6—bronchus—esophageal cancer	0.000256	0.00913	CbGeAlD
Dexamethasone—NR3C1—bronchus—esophageal cancer	0.000255	0.00912	CbGeAlD
Dexamethasone—CYP2C19—digestive system—esophageal cancer	0.000252	0.00901	CbGeAlD
Dexamethasone—Hiccups—Capecitabine—esophageal cancer	0.000252	0.00449	CcSEcCtD
Dexamethasone—NR3C1—smooth muscle tissue—esophageal cancer	0.00025	0.00892	CbGeAlD
Dexamethasone—Fungal infection—Methotrexate—esophageal cancer	0.000243	0.00433	CcSEcCtD
Dexamethasone—Skin exfoliation—Capecitabine—esophageal cancer	0.000241	0.00429	CcSEcCtD
Dexamethasone—CYP1B1—lung—esophageal cancer	0.00024	0.00858	CbGeAlD
Dexamethasone—Fluid retention—Capecitabine—esophageal cancer	0.000239	0.00426	CcSEcCtD
Dexamethasone—Necrosis—Methotrexate—esophageal cancer	0.000239	0.00426	CcSEcCtD
Dexamethasone—Abscess—Methotrexate—esophageal cancer	0.000237	0.00423	CcSEcCtD
Dexamethasone—Irritability—Cisplatin—esophageal cancer	0.000237	0.00422	CcSEcCtD
Dexamethasone—Neuropathy—Capecitabine—esophageal cancer	0.000237	0.00422	CcSEcCtD
Dexamethasone—CYP1A1—trachea—esophageal cancer	0.000236	0.00844	CbGeAlD
Dexamethasone—Dry eye—Capecitabine—esophageal cancer	0.000233	0.00415	CcSEcCtD
Dexamethasone—Oesophagitis—Capecitabine—esophageal cancer	0.00023	0.0041	CcSEcCtD
Dexamethasone—NR3C1—trachea—esophageal cancer	0.000229	0.00819	CbGeAlD
Dexamethasone—Petechiae—Methotrexate—esophageal cancer	0.000228	0.00406	CcSEcCtD
Dexamethasone—Ecchymosis—Capecitabine—esophageal cancer	0.000228	0.00406	CcSEcCtD
Dexamethasone—Hypokalaemia—Cisplatin—esophageal cancer	0.000226	0.00402	CcSEcCtD
Dexamethasone—PTGS2—epithelium—esophageal cancer	0.000224	0.00801	CbGeAlD
Dexamethasone—PTGS2—bronchus—esophageal cancer	0.000221	0.00789	CbGeAlD
Dexamethasone—PTGS2—smooth muscle tissue—esophageal cancer	0.000216	0.00772	CbGeAlD
Dexamethasone—Extravasation—Methotrexate—esophageal cancer	0.000215	0.00383	CcSEcCtD
Dexamethasone—Thrombophlebitis—Capecitabine—esophageal cancer	0.000211	0.00377	CcSEcCtD
Dexamethasone—Diabetes mellitus—Capecitabine—esophageal cancer	0.00021	0.00375	CcSEcCtD
Dexamethasone—NR3C2—lymph node—esophageal cancer	0.00021	0.0075	CbGeAlD
Dexamethasone—Sweating increased—Cisplatin—esophageal cancer	0.000209	0.00372	CcSEcCtD
Dexamethasone—Herpes simplex—Methotrexate—esophageal cancer	0.000204	0.00363	CcSEcCtD
Dexamethasone—CYP1A1—digestive system—esophageal cancer	0.000203	0.00726	CbGeAlD
Dexamethasone—Eye pain—Capecitabine—esophageal cancer	0.000203	0.00361	CcSEcCtD
Dexamethasone—CYP3A5—digestive system—esophageal cancer	0.000199	0.0071	CbGeAlD
Dexamethasone—Ulcer—Methotrexate—esophageal cancer	0.000198	0.00353	CcSEcCtD
Dexamethasone—PTGS2—trachea—esophageal cancer	0.000198	0.00709	CbGeAlD
Dexamethasone—CYP2B6—digestive system—esophageal cancer	0.000197	0.00705	CbGeAlD
Dexamethasone—NR3C1—digestive system—esophageal cancer	0.000197	0.00704	CbGeAlD
Dexamethasone—CYP2C9—digestive system—esophageal cancer	0.000196	0.00699	CbGeAlD
Dexamethasone—PGR—lymph node—esophageal cancer	0.000195	0.00697	CbGeAlD
Dexamethasone—Increased appetite—Capecitabine—esophageal cancer	0.000195	0.00347	CcSEcCtD
Dexamethasone—Vasculitis—Methotrexate—esophageal cancer	0.000192	0.00343	CcSEcCtD
Dexamethasone—Dermatitis bullous—Capecitabine—esophageal cancer	0.000191	0.00341	CcSEcCtD
Dexamethasone—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000189	0.00336	CcSEcCtD
Dexamethasone—Myocardial infarction—Cisplatin—esophageal cancer	0.000188	0.00334	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000188	0.00334	CcSEcCtD
Dexamethasone—Cardiac failure—Capecitabine—esophageal cancer	0.000188	0.00334	CcSEcCtD
Dexamethasone—Lethargy—Capecitabine—esophageal cancer	0.000187	0.00333	CcSEcCtD
Dexamethasone—Conjunctivitis—Cisplatin—esophageal cancer	0.000186	0.00331	CcSEcCtD
Dexamethasone—CYP2E1—digestive system—esophageal cancer	0.000185	0.00662	CbGeAlD
Dexamethasone—Osteoarthritis—Capecitabine—esophageal cancer	0.000183	0.00326	CcSEcCtD
Dexamethasone—Migraine—Capecitabine—esophageal cancer	0.00018	0.00321	CcSEcCtD
Dexamethasone—Skin exfoliation—Methotrexate—esophageal cancer	0.000179	0.00319	CcSEcCtD
Dexamethasone—ABCG2—lung—esophageal cancer	0.000179	0.00639	CbGeAlD
Dexamethasone—CYP19A1—lymph node—esophageal cancer	0.000176	0.00627	CbGeAlD
Dexamethasone—Bradycardia—Cisplatin—esophageal cancer	0.000175	0.00311	CcSEcCtD
Dexamethasone—Irritability—Capecitabine—esophageal cancer	0.000175	0.00311	CcSEcCtD
Dexamethasone—Cardiac arrest—Capecitabine—esophageal cancer	0.000174	0.0031	CcSEcCtD
Dexamethasone—Mood swings—Capecitabine—esophageal cancer	0.000173	0.00309	CcSEcCtD
Dexamethasone—PTGS2—digestive system—esophageal cancer	0.000171	0.0061	CbGeAlD
Dexamethasone—Ecchymosis—Methotrexate—esophageal cancer	0.00017	0.00302	CcSEcCtD
Dexamethasone—CYP1A1—lung—esophageal cancer	0.00017	0.00606	CbGeAlD
Dexamethasone—Dry skin—Capecitabine—esophageal cancer	0.000168	0.00299	CcSEcCtD
Dexamethasone—ABCC2—lymph node—esophageal cancer	0.000168	0.00599	CbGeAlD
Dexamethasone—Pulmonary oedema—Methotrexate—esophageal cancer	0.000167	0.00298	CcSEcCtD
Dexamethasone—Hypokalaemia—Capecitabine—esophageal cancer	0.000167	0.00297	CcSEcCtD
Dexamethasone—CYP3A5—lung—esophageal cancer	0.000166	0.00593	CbGeAlD
Dexamethasone—Visual impairment—Cisplatin—esophageal cancer	0.000166	0.00295	CcSEcCtD
Dexamethasone—CYP2B6—lung—esophageal cancer	0.000165	0.00589	CbGeAlD
Dexamethasone—NR3C1—lung—esophageal cancer	0.000165	0.00588	CbGeAlD
Dexamethasone—CYP1B1—lymph node—esophageal cancer	0.000164	0.00587	CbGeAlD
Dexamethasone—Muscular weakness—Capecitabine—esophageal cancer	0.000161	0.00288	CcSEcCtD
Dexamethasone—Eye disorder—Cisplatin—esophageal cancer	0.000161	0.00286	CcSEcCtD
Dexamethasone—Thrombophlebitis—Methotrexate—esophageal cancer	0.000157	0.0028	CcSEcCtD
Dexamethasone—Diabetes mellitus—Methotrexate—esophageal cancer	0.000157	0.00279	CcSEcCtD
Dexamethasone—CYP2E1—lung—esophageal cancer	0.000155	0.00553	CbGeAlD
Dexamethasone—Sweating increased—Capecitabine—esophageal cancer	0.000154	0.00274	CcSEcCtD
Dexamethasone—Arrhythmia—Cisplatin—esophageal cancer	0.000153	0.00273	CcSEcCtD
Dexamethasone—Alopecia—Cisplatin—esophageal cancer	0.000152	0.0027	CcSEcCtD
Dexamethasone—Erythema—Cisplatin—esophageal cancer	0.00015	0.00266	CcSEcCtD
Dexamethasone—CYP3A4—digestive system—esophageal cancer	0.000149	0.00533	CbGeAlD
Dexamethasone—CYP2D6—digestive system—esophageal cancer	0.000147	0.00524	CbGeAlD
Dexamethasone—Weight increased—Capecitabine—esophageal cancer	0.000144	0.00256	CcSEcCtD
Dexamethasone—Visual disturbance—Methotrexate—esophageal cancer	0.000144	0.00256	CcSEcCtD
Dexamethasone—Weight decreased—Capecitabine—esophageal cancer	0.000143	0.00255	CcSEcCtD
Dexamethasone—Hyperglycaemia—Capecitabine—esophageal cancer	0.000143	0.00254	CcSEcCtD
Dexamethasone—PTGS2—lung—esophageal cancer	0.000142	0.00509	CbGeAlD
Dexamethasone—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000141	0.00251	CcSEcCtD
Dexamethasone—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000139	0.00248	CcSEcCtD
Dexamethasone—Lethargy—Methotrexate—esophageal cancer	0.000139	0.00248	CcSEcCtD
Dexamethasone—Prednisolone—CYP2A6—esophageal cancer	0.000139	0.0614	CrCbGaD
Dexamethasone—Ill-defined disorder—Cisplatin—esophageal cancer	0.000139	0.00247	CcSEcCtD
Dexamethasone—ABCB1—epithelium—esophageal cancer	0.000139	0.00496	CbGeAlD
Dexamethasone—Myocardial infarction—Capecitabine—esophageal cancer	0.000138	0.00246	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000138	0.00246	CcSEcCtD
Dexamethasone—Conjunctivitis—Capecitabine—esophageal cancer	0.000137	0.00244	CcSEcCtD
Dexamethasone—Osteoarthritis—Methotrexate—esophageal cancer	0.000136	0.00243	CcSEcCtD
Dexamethasone—Malaise—Cisplatin—esophageal cancer	0.000135	0.0024	CcSEcCtD
Dexamethasone—Irritability—Methotrexate—esophageal cancer	0.00013	0.00232	CcSEcCtD
Dexamethasone—Convulsion—Cisplatin—esophageal cancer	0.00013	0.00231	CcSEcCtD
Dexamethasone—Betamethasone—CYP19A1—esophageal cancer	0.000129	0.0573	CrCbGaD
Dexamethasone—Mood swings—Methotrexate—esophageal cancer	0.000129	0.0023	CcSEcCtD
Dexamethasone—Bradycardia—Capecitabine—esophageal cancer	0.000129	0.0023	CcSEcCtD
Dexamethasone—Myalgia—Cisplatin—esophageal cancer	0.000127	0.00227	CcSEcCtD
Dexamethasone—Haemoglobin—Capecitabine—esophageal cancer	0.000127	0.00227	CcSEcCtD
Dexamethasone—Anxiety—Cisplatin—esophageal cancer	0.000127	0.00226	CcSEcCtD
Dexamethasone—Haemorrhage—Capecitabine—esophageal cancer	0.000127	0.00226	CcSEcCtD
Dexamethasone—Discomfort—Cisplatin—esophageal cancer	0.000126	0.00224	CcSEcCtD
Dexamethasone—ABCB1—trachea—esophageal cancer	0.000123	0.00438	CbGeAlD
Dexamethasone—ABCG2—lymph node—esophageal cancer	0.000122	0.00437	CbGeAlD
Dexamethasone—Anaphylactic shock—Cisplatin—esophageal cancer	0.000122	0.00217	CcSEcCtD
Dexamethasone—Oedema—Cisplatin—esophageal cancer	0.000122	0.00217	CcSEcCtD
Dexamethasone—Visual impairment—Capecitabine—esophageal cancer	0.000122	0.00217	CcSEcCtD
Dexamethasone—Infection—Cisplatin—esophageal cancer	0.000121	0.00216	CcSEcCtD
Dexamethasone—Nervous system disorder—Cisplatin—esophageal cancer	0.00012	0.00213	CcSEcCtD
Dexamethasone—Thrombocytopenia—Cisplatin—esophageal cancer	0.000119	0.00213	CcSEcCtD
Dexamethasone—Tachycardia—Cisplatin—esophageal cancer	0.000119	0.00212	CcSEcCtD
Dexamethasone—Eye disorder—Capecitabine—esophageal cancer	0.000118	0.00211	CcSEcCtD
Dexamethasone—Hyperhidrosis—Cisplatin—esophageal cancer	0.000118	0.0021	CcSEcCtD
Dexamethasone—Anorexia—Cisplatin—esophageal cancer	0.000116	0.00207	CcSEcCtD
Dexamethasone—CYP1A1—lymph node—esophageal cancer	0.000116	0.00415	CbGeAlD
Dexamethasone—Angiopathy—Capecitabine—esophageal cancer	0.000115	0.00205	CcSEcCtD
Dexamethasone—Hypotension—Cisplatin—esophageal cancer	0.000114	0.00203	CcSEcCtD
Dexamethasone—Arrhythmia—Capecitabine—esophageal cancer	0.000113	0.00201	CcSEcCtD
Dexamethasone—NR3C1—lymph node—esophageal cancer	0.000113	0.00402	CbGeAlD
Dexamethasone—Alopecia—Capecitabine—esophageal cancer	0.000112	0.00199	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000111	0.00198	CcSEcCtD
Dexamethasone—Erythema—Capecitabine—esophageal cancer	0.00011	0.00196	CcSEcCtD
Dexamethasone—Paraesthesia—Cisplatin—esophageal cancer	0.00011	0.00195	CcSEcCtD
Dexamethasone—Decreased appetite—Cisplatin—esophageal cancer	0.000106	0.00189	CcSEcCtD
Dexamethasone—ABCB1—digestive system—esophageal cancer	0.000106	0.00377	CbGeAlD
Dexamethasone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000105	0.00188	CcSEcCtD
Dexamethasone—Pain—Cisplatin—esophageal cancer	0.000104	0.00186	CcSEcCtD
Dexamethasone—Ill-defined disorder—Capecitabine—esophageal cancer	0.000102	0.00182	CcSEcCtD
Dexamethasone—Conjunctivitis—Methotrexate—esophageal cancer	0.000102	0.00182	CcSEcCtD
Dexamethasone—Feeling abnormal—Cisplatin—esophageal cancer	0.000101	0.00179	CcSEcCtD
Dexamethasone—Malaise—Capecitabine—esophageal cancer	9.94e-05	0.00177	CcSEcCtD
Dexamethasone—Vertigo—Capecitabine—esophageal cancer	9.9e-05	0.00176	CcSEcCtD
Dexamethasone—Syncope—Capecitabine—esophageal cancer	9.88e-05	0.00176	CcSEcCtD
Dexamethasone—PTGS2—lymph node—esophageal cancer	9.74e-05	0.00348	CbGeAlD
Dexamethasone—Loss of consciousness—Capecitabine—esophageal cancer	9.69e-05	0.00173	CcSEcCtD
Dexamethasone—Body temperature increased—Cisplatin—esophageal cancer	9.65e-05	0.00172	CcSEcCtD
Dexamethasone—Hypertension—Capecitabine—esophageal cancer	9.52e-05	0.00169	CcSEcCtD
Dexamethasone—Haemoglobin—Methotrexate—esophageal cancer	9.47e-05	0.00169	CcSEcCtD
Dexamethasone—Haemorrhage—Methotrexate—esophageal cancer	9.43e-05	0.00168	CcSEcCtD
Dexamethasone—Myalgia—Capecitabine—esophageal cancer	9.38e-05	0.00167	CcSEcCtD
Dexamethasone—Anxiety—Capecitabine—esophageal cancer	9.35e-05	0.00167	CcSEcCtD
Dexamethasone—Discomfort—Capecitabine—esophageal cancer	9.27e-05	0.00165	CcSEcCtD
Dexamethasone—Fluticasone furoate—ABCB1—esophageal cancer	9.19e-05	0.0407	CrCbGaD
Dexamethasone—Visual impairment—Methotrexate—esophageal cancer	9.08e-05	0.00162	CcSEcCtD
Dexamethasone—Oedema—Capecitabine—esophageal cancer	9e-05	0.0016	CcSEcCtD
Dexamethasone—Infection—Capecitabine—esophageal cancer	8.94e-05	0.00159	CcSEcCtD
Dexamethasone—Shock—Capecitabine—esophageal cancer	8.85e-05	0.00158	CcSEcCtD
Dexamethasone—Nervous system disorder—Capecitabine—esophageal cancer	8.82e-05	0.00157	CcSEcCtD
Dexamethasone—ABCB1—lung—esophageal cancer	8.81e-05	0.00315	CbGeAlD
Dexamethasone—Eye disorder—Methotrexate—esophageal cancer	8.81e-05	0.00157	CcSEcCtD
Dexamethasone—Thrombocytopenia—Capecitabine—esophageal cancer	8.81e-05	0.00157	CcSEcCtD
Dexamethasone—Tachycardia—Capecitabine—esophageal cancer	8.78e-05	0.00156	CcSEcCtD
Dexamethasone—Asthenia—Cisplatin—esophageal cancer	8.76e-05	0.00156	CcSEcCtD
Dexamethasone—Hyperhidrosis—Capecitabine—esophageal cancer	8.7e-05	0.00155	CcSEcCtD
Dexamethasone—Anorexia—Capecitabine—esophageal cancer	8.57e-05	0.00153	CcSEcCtD
Dexamethasone—Angiopathy—Methotrexate—esophageal cancer	8.55e-05	0.00152	CcSEcCtD
Dexamethasone—Hypotension—Capecitabine—esophageal cancer	8.41e-05	0.0015	CcSEcCtD
Dexamethasone—Diarrhoea—Cisplatin—esophageal cancer	8.35e-05	0.00149	CcSEcCtD
Dexamethasone—Alopecia—Methotrexate—esophageal cancer	8.33e-05	0.00148	CcSEcCtD
Dexamethasone—Erythema—Methotrexate—esophageal cancer	8.2e-05	0.00146	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	8.2e-05	0.00146	CcSEcCtD
Dexamethasone—Insomnia—Capecitabine—esophageal cancer	8.14e-05	0.00145	CcSEcCtD
Dexamethasone—Paraesthesia—Capecitabine—esophageal cancer	8.08e-05	0.00144	CcSEcCtD
Dexamethasone—Dyspepsia—Capecitabine—esophageal cancer	7.92e-05	0.00141	CcSEcCtD
Dexamethasone—Decreased appetite—Capecitabine—esophageal cancer	7.82e-05	0.00139	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Capecitabine—esophageal cancer	7.77e-05	0.00138	CcSEcCtD
Dexamethasone—Vomiting—Cisplatin—esophageal cancer	7.76e-05	0.00138	CcSEcCtD
Dexamethasone—Fatigue—Capecitabine—esophageal cancer	7.76e-05	0.00138	CcSEcCtD
Dexamethasone—Rash—Cisplatin—esophageal cancer	7.69e-05	0.00137	CcSEcCtD
Dexamethasone—Pain—Capecitabine—esophageal cancer	7.69e-05	0.00137	CcSEcCtD
Dexamethasone—Dermatitis—Cisplatin—esophageal cancer	7.69e-05	0.00137	CcSEcCtD
Dexamethasone—Ill-defined disorder—Methotrexate—esophageal cancer	7.61e-05	0.00136	CcSEcCtD
Dexamethasone—Feeling abnormal—Capecitabine—esophageal cancer	7.41e-05	0.00132	CcSEcCtD
Dexamethasone—Malaise—Methotrexate—esophageal cancer	7.4e-05	0.00132	CcSEcCtD
Dexamethasone—Vertigo—Methotrexate—esophageal cancer	7.37e-05	0.00131	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Capecitabine—esophageal cancer	7.36e-05	0.00131	CcSEcCtD
Dexamethasone—Methylprednisolone—ABCB1—esophageal cancer	7.33e-05	0.0324	CrCbGaD
Dexamethasone—Triamcinolone—PTGS2—esophageal cancer	7.27e-05	0.0322	CrCbGaD
Dexamethasone—Nausea—Cisplatin—esophageal cancer	7.25e-05	0.00129	CcSEcCtD
Dexamethasone—Urticaria—Capecitabine—esophageal cancer	7.15e-05	0.00127	CcSEcCtD
Dexamethasone—Body temperature increased—Capecitabine—esophageal cancer	7.11e-05	0.00127	CcSEcCtD
Dexamethasone—Abdominal pain—Capecitabine—esophageal cancer	7.11e-05	0.00127	CcSEcCtD
Dexamethasone—Convulsion—Methotrexate—esophageal cancer	7.11e-05	0.00127	CcSEcCtD
Dexamethasone—Myalgia—Methotrexate—esophageal cancer	6.99e-05	0.00124	CcSEcCtD
Dexamethasone—Discomfort—Methotrexate—esophageal cancer	6.9e-05	0.00123	CcSEcCtD
Dexamethasone—Anaphylactic shock—Methotrexate—esophageal cancer	6.7e-05	0.00119	CcSEcCtD
Dexamethasone—Infection—Methotrexate—esophageal cancer	6.65e-05	0.00118	CcSEcCtD
Dexamethasone—Nervous system disorder—Methotrexate—esophageal cancer	6.57e-05	0.00117	CcSEcCtD
Dexamethasone—Thrombocytopenia—Methotrexate—esophageal cancer	6.56e-05	0.00117	CcSEcCtD
Dexamethasone—Hyperhidrosis—Methotrexate—esophageal cancer	6.47e-05	0.00115	CcSEcCtD
Dexamethasone—Asthenia—Capecitabine—esophageal cancer	6.45e-05	0.00115	CcSEcCtD
Dexamethasone—Anorexia—Methotrexate—esophageal cancer	6.38e-05	0.00114	CcSEcCtD
Dexamethasone—Pruritus—Capecitabine—esophageal cancer	6.36e-05	0.00113	CcSEcCtD
Dexamethasone—Hypotension—Methotrexate—esophageal cancer	6.26e-05	0.00111	CcSEcCtD
Dexamethasone—Diarrhoea—Capecitabine—esophageal cancer	6.15e-05	0.0011	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	6.1e-05	0.00109	CcSEcCtD
Dexamethasone—Insomnia—Methotrexate—esophageal cancer	6.06e-05	0.00108	CcSEcCtD
Dexamethasone—ABCB1—lymph node—esophageal cancer	6.03e-05	0.00215	CbGeAlD
Dexamethasone—Paraesthesia—Methotrexate—esophageal cancer	6.01e-05	0.00107	CcSEcCtD
Dexamethasone—Betamethasone—PTGS2—esophageal cancer	5.95e-05	0.0263	CrCbGaD
Dexamethasone—Dizziness—Capecitabine—esophageal cancer	5.95e-05	0.00106	CcSEcCtD
Dexamethasone—Dyspepsia—Methotrexate—esophageal cancer	5.89e-05	0.00105	CcSEcCtD
Dexamethasone—Decreased appetite—Methotrexate—esophageal cancer	5.82e-05	0.00104	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Methotrexate—esophageal cancer	5.78e-05	0.00103	CcSEcCtD
Dexamethasone—Fatigue—Methotrexate—esophageal cancer	5.77e-05	0.00103	CcSEcCtD
Dexamethasone—Pain—Methotrexate—esophageal cancer	5.73e-05	0.00102	CcSEcCtD
Dexamethasone—Vomiting—Capecitabine—esophageal cancer	5.72e-05	0.00102	CcSEcCtD
Dexamethasone—Rash—Capecitabine—esophageal cancer	5.67e-05	0.00101	CcSEcCtD
Dexamethasone—Dermatitis—Capecitabine—esophageal cancer	5.67e-05	0.00101	CcSEcCtD
Dexamethasone—Headache—Capecitabine—esophageal cancer	5.64e-05	0.001	CcSEcCtD
Dexamethasone—Prednisone—ABCB1—esophageal cancer	5.6e-05	0.0248	CrCbGaD
Dexamethasone—Feeling abnormal—Methotrexate—esophageal cancer	5.52e-05	0.000983	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Methotrexate—esophageal cancer	5.48e-05	0.000975	CcSEcCtD
Dexamethasone—Nausea—Capecitabine—esophageal cancer	5.34e-05	0.000952	CcSEcCtD
Dexamethasone—Urticaria—Methotrexate—esophageal cancer	5.32e-05	0.000948	CcSEcCtD
Dexamethasone—Abdominal pain—Methotrexate—esophageal cancer	5.29e-05	0.000943	CcSEcCtD
Dexamethasone—Body temperature increased—Methotrexate—esophageal cancer	5.29e-05	0.000943	CcSEcCtD
Dexamethasone—Prednisolone—ABCB1—esophageal cancer	5.16e-05	0.0229	CrCbGaD
Dexamethasone—Betamethasone—ABCB1—esophageal cancer	5.06e-05	0.0224	CrCbGaD
Dexamethasone—Asthenia—Methotrexate—esophageal cancer	4.8e-05	0.000856	CcSEcCtD
Dexamethasone—Pruritus—Methotrexate—esophageal cancer	4.74e-05	0.000844	CcSEcCtD
Dexamethasone—Diarrhoea—Methotrexate—esophageal cancer	4.58e-05	0.000816	CcSEcCtD
Dexamethasone—Dizziness—Methotrexate—esophageal cancer	4.43e-05	0.000789	CcSEcCtD
Dexamethasone—Vomiting—Methotrexate—esophageal cancer	4.26e-05	0.000758	CcSEcCtD
Dexamethasone—Rash—Methotrexate—esophageal cancer	4.22e-05	0.000752	CcSEcCtD
Dexamethasone—Dermatitis—Methotrexate—esophageal cancer	4.22e-05	0.000751	CcSEcCtD
Dexamethasone—Headache—Methotrexate—esophageal cancer	4.19e-05	0.000747	CcSEcCtD
Dexamethasone—Nausea—Methotrexate—esophageal cancer	3.98e-05	0.000708	CcSEcCtD
Dexamethasone—Hydrocortisone—ABCB1—esophageal cancer	3.95e-05	0.0175	CrCbGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.37e-06	3.46e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—HMOX1—esophageal cancer	3.37e-06	3.46e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—GSTT1—esophageal cancer	3.36e-06	3.46e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—PTGS2—esophageal cancer	3.35e-06	3.45e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CYP2A6—esophageal cancer	3.33e-06	3.42e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—PTGS2—esophageal cancer	3.32e-06	3.41e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.31e-06	3.41e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CA2—esophageal cancer	3.31e-06	3.4e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—CYP1B1—esophageal cancer	3.29e-06	3.39e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GNG7—esophageal cancer	3.29e-06	3.38e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GAPDH—esophageal cancer	3.29e-06	3.38e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GAPDH—esophageal cancer	3.26e-06	3.35e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CRABP1—esophageal cancer	3.26e-06	3.35e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—SMAD4—esophageal cancer	3.24e-06	3.33e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—ABCB1—esophageal cancer	3.23e-06	3.32e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CRABP1—esophageal cancer	3.23e-06	3.32e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—NOS3—esophageal cancer	3.22e-06	3.31e-05	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—PIK3CA—esophageal cancer	3.19e-06	3.28e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—CYP1B1—esophageal cancer	3.17e-06	3.25e-05	CbGpPWpGaD
Dexamethasone—PGR—Gene Expression—MYC—esophageal cancer	3.16e-06	3.25e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—ALDH2—esophageal cancer	3.16e-06	3.25e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—ENO1—esophageal cancer	3.15e-06	3.24e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PTGS1—esophageal cancer	3.15e-06	3.24e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PSME2—esophageal cancer	3.11e-06	3.19e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PSME1—esophageal cancer	3.11e-06	3.19e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—CYP1B1—esophageal cancer	3.1e-06	3.19e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GNG7—esophageal cancer	3.1e-06	3.19e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—NOS3—esophageal cancer	3.1e-06	3.19e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—CYP19A1—esophageal cancer	3.1e-06	3.18e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—CYP1B1—esophageal cancer	3.09e-06	3.18e-05	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—TP53—esophageal cancer	3.09e-06	3.17e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—ALDH2—esophageal cancer	3.08e-06	3.17e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—CREBBP—esophageal cancer	3.08e-06	3.16e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PLCE1—esophageal cancer	3.07e-06	3.16e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ADH7—esophageal cancer	3.07e-06	3.16e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GNG7—esophageal cancer	3.07e-06	3.16e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.07e-06	3.16e-05	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—EP300—esophageal cancer	3.05e-06	3.14e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GSTT1—esophageal cancer	3e-06	3.09e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—CREBBP—esophageal cancer	3e-06	3.09e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—CYP19A1—esophageal cancer	2.98e-06	3.06e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CYP2A6—esophageal cancer	2.97e-06	3.05e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.96e-06	3.04e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.96e-06	3.04e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.96e-06	3.04e-05	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—PIK3CA—esophageal cancer	2.95e-06	3.03e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PTGS2—esophageal cancer	2.94e-06	3.03e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GSTT1—esophageal cancer	2.93e-06	3.01e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—CYP1B1—esophageal cancer	2.92e-06	3.01e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—CYP19A1—esophageal cancer	2.92e-06	3e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—CYP19A1—esophageal cancer	2.91e-06	2.99e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ALDH2—esophageal cancer	2.9e-06	2.98e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—ERBB2—esophageal cancer	2.9e-06	2.98e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.9e-06	2.98e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ALDH2—esophageal cancer	2.88e-06	2.96e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—HMOX1—esophageal cancer	2.83e-06	2.91e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PTGS1—esophageal cancer	2.81e-06	2.89e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—ENO1—esophageal cancer	2.81e-06	2.89e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—EP300—esophageal cancer	2.79e-06	2.87e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.77e-06	2.85e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PSME2—esophageal cancer	2.77e-06	2.85e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PSME1—esophageal cancer	2.77e-06	2.85e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.76e-06	2.84e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—EP300—esophageal cancer	2.76e-06	2.84e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—CYP19A1—esophageal cancer	2.75e-06	2.83e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PTGS1—esophageal cancer	2.75e-06	2.82e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—ENO1—esophageal cancer	2.75e-06	2.82e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.74e-06	2.82e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GSTT1—esophageal cancer	2.74e-06	2.81e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.73e-06	2.81e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—HMOX1—esophageal cancer	2.72e-06	2.79e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—CREBBP—esophageal cancer	2.71e-06	2.79e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—ABCB1—esophageal cancer	2.71e-06	2.79e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.71e-06	2.79e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CYP2A6—esophageal cancer	2.71e-06	2.78e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PSME2—esophageal cancer	2.71e-06	2.78e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PSME1—esophageal cancer	2.71e-06	2.78e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.7e-06	2.77e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.69e-06	2.77e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—NOS3—esophageal cancer	2.69e-06	2.76e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CYP1B1—esophageal cancer	2.68e-06	2.76e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—HMOX1—esophageal cancer	2.66e-06	2.74e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—HMOX1—esophageal cancer	2.66e-06	2.73e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—HIF1A—esophageal cancer	2.65e-06	2.72e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—CREBBP—esophageal cancer	2.61e-06	2.69e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—ABCB1—esophageal cancer	2.61e-06	2.68e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.59e-06	2.66e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ENO1—esophageal cancer	2.59e-06	2.66e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—TYMP—esophageal cancer	2.58e-06	2.65e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PTGS1—esophageal cancer	2.57e-06	2.64e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ENO1—esophageal cancer	2.57e-06	2.64e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CCND1—esophageal cancer	2.56e-06	2.63e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—ABCB1—esophageal cancer	2.55e-06	2.63e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PSME2—esophageal cancer	2.55e-06	2.62e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PSME1—esophageal cancer	2.55e-06	2.62e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—ABCB1—esophageal cancer	2.55e-06	2.62e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PSME2—esophageal cancer	2.53e-06	2.6e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PSME1—esophageal cancer	2.53e-06	2.6e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CYP19A1—esophageal cancer	2.52e-06	2.59e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—HMOX1—esophageal cancer	2.51e-06	2.58e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.51e-06	2.58e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CDKN1A—esophageal cancer	2.48e-06	2.55e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.46e-06	2.53e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PTGS2—esophageal cancer	2.46e-06	2.53e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—EP300—esophageal cancer	2.45e-06	2.52e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.44e-06	2.51e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—NOS3—esophageal cancer	2.43e-06	2.5e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.42e-06	2.49e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—NOS2—esophageal cancer	2.41e-06	2.48e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—ABCB1—esophageal cancer	2.41e-06	2.48e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CYP1B1—esophageal cancer	2.39e-06	2.46e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—NOTCH1—esophageal cancer	2.39e-06	2.45e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—CREBBP—esophageal cancer	2.38e-06	2.44e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—EP300—esophageal cancer	2.36e-06	2.42e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—CREBBP—esophageal cancer	2.36e-06	2.42e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—NOS3—esophageal cancer	2.34e-06	2.4e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.34e-06	2.4e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—TPI1—esophageal cancer	2.33e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.33e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—HMOX1—esophageal cancer	2.3e-06	2.36e-05	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—PIK3CA—esophageal cancer	2.26e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.26e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CYP19A1—esophageal cancer	2.25e-06	2.31e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.23e-06	2.3e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PTGS2—esophageal cancer	2.22e-06	2.28e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.21e-06	2.27e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—ABCB1—esophageal cancer	2.21e-06	2.27e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.2e-06	2.26e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.2e-06	2.26e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CYP1B1—esophageal cancer	2.18e-06	2.24e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CREBBP—esophageal cancer	2.16e-06	2.23e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—CREBBP—esophageal cancer	2.16e-06	2.22e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.15e-06	2.21e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PTGS2—esophageal cancer	2.14e-06	2.2e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.13e-06	2.19e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—NOS3—esophageal cancer	2.13e-06	2.19e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—NOS3—esophageal cancer	2.11e-06	2.17e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.07e-06	2.13e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—PIK3CA—esophageal cancer	2.06e-06	2.12e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MYC—esophageal cancer	2.05e-06	2.11e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—HMOX1—esophageal cancer	2.05e-06	2.11e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CYP19A1—esophageal cancer	2.05e-06	2.11e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.05e-06	2.11e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—EP300—esophageal cancer	2.04e-06	2.1e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—PIK3CA—esophageal cancer	2.04e-06	2.1e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GNG7—esophageal cancer	2.03e-06	2.08e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.01e-06	2.07e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—EGFR—esophageal cancer	2.01e-06	2.07e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—HMOX1—esophageal cancer	2e-06	2.06e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.97e-06	2.03e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PTGS2—esophageal cancer	1.95e-06	2e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—NOS3—esophageal cancer	1.94e-06	1.99e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—NOS3—esophageal cancer	1.93e-06	1.99e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.93e-06	1.98e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.9e-06	1.95e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.89e-06	1.94e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.87e-06	1.92e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—EP300—esophageal cancer	1.85e-06	1.9e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.84e-06	1.89e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—MYC—esophageal cancer	1.83e-06	1.88e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.82e-06	1.87e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—CREBBP—esophageal cancer	1.81e-06	1.86e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—ERBB2—esophageal cancer	1.81e-06	1.86e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.81e-06	1.86e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PIK3CA—esophageal cancer	1.81e-06	1.86e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.81e-06	1.86e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.8e-06	1.85e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.78e-06	1.83e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—EP300—esophageal cancer	1.78e-06	1.83e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PTGS2—esophageal cancer	1.77e-06	1.82e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PIK3CA—esophageal cancer	1.74e-06	1.79e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—CREBBP—esophageal cancer	1.74e-06	1.79e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—CREBBP—esophageal cancer	1.71e-06	1.75e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.7e-06	1.75e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.69e-06	1.74e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ENO1—esophageal cancer	1.69e-06	1.74e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—TP53—esophageal cancer	1.69e-06	1.73e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.67e-06	1.72e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PSME2—esophageal cancer	1.67e-06	1.71e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PSME1—esophageal cancer	1.67e-06	1.71e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—NOS3—esophageal cancer	1.62e-06	1.67e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—EP300—esophageal cancer	1.62e-06	1.66e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—CREBBP—esophageal cancer	1.61e-06	1.65e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—EP300—esophageal cancer	1.6e-06	1.65e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—NOS3—esophageal cancer	1.56e-06	1.6e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CDKN1A—esophageal cancer	1.55e-06	1.59e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—NOS3—esophageal cancer	1.53e-06	1.57e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—NOS3—esophageal cancer	1.53e-06	1.57e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PIK3CA—esophageal cancer	1.51e-06	1.55e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.49e-06	1.53e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CREBBP—esophageal cancer	1.48e-06	1.52e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—EP300—esophageal cancer	1.47e-06	1.52e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—EP300—esophageal cancer	1.47e-06	1.51e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—NOS3—esophageal cancer	1.44e-06	1.48e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.44e-06	1.48e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PTGS2—esophageal cancer	1.43e-06	1.47e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PTGS2—esophageal cancer	1.4e-06	1.44e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.39e-06	1.43e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PIK3CA—esophageal cancer	1.37e-06	1.41e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.36e-06	1.4e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—NOS3—esophageal cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PTGS2—esophageal cancer	1.32e-06	1.35e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.32e-06	1.35e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PIK3CA—esophageal cancer	1.32e-06	1.35e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CREBBP—esophageal cancer	1.29e-06	1.32e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MYC—esophageal cancer	1.28e-06	1.32e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—EGFR—esophageal cancer	1.26e-06	1.29e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—EP300—esophageal cancer	1.23e-06	1.27e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.23e-06	1.27e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.21e-06	1.25e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PTGS2—esophageal cancer	1.21e-06	1.24e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PIK3CA—esophageal cancer	1.19e-06	1.22e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—EP300—esophageal cancer	1.19e-06	1.22e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.18e-06	1.22e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—NOS3—esophageal cancer	1.18e-06	1.21e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—EP300—esophageal cancer	1.16e-06	1.19e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—EP300—esophageal cancer	1.16e-06	1.19e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—NOS3—esophageal cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—EP300—esophageal cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PIK3CA—esophageal cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CA—esophageal cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—NOS3—esophageal cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—NOS3—esophageal cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PTGS2—esophageal cancer	1.05e-06	1.08e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—EP300—esophageal cancer	1e-06	1.03e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PTGS2—esophageal cancer	9.92e-07	1.02e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PTGS2—esophageal cancer	9.83e-07	1.01e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CA—esophageal cancer	9.13e-07	9.39e-06	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—EP300—esophageal cancer	8.97e-07	9.22e-06	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CA—esophageal cancer	8.78e-07	9.02e-06	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—EP300—esophageal cancer	8.75e-07	9e-06	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CA—esophageal cancer	8.6e-07	8.84e-06	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CA—esophageal cancer	8.58e-07	8.82e-06	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—EP300—esophageal cancer	8.25e-07	8.48e-06	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—EP300—esophageal cancer	8.18e-07	8.41e-06	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CA—esophageal cancer	8.11e-07	8.33e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CREBBP—esophageal cancer	7.92e-07	8.14e-06	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CA—esophageal cancer	7.43e-07	7.64e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—NOS3—esophageal cancer	7.09e-07	7.29e-06	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CA—esophageal cancer	6.63e-07	6.82e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.48e-07	6.67e-06	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.48e-07	6.66e-06	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CA—esophageal cancer	6.1e-07	6.27e-06	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CA—esophageal cancer	6.05e-07	6.22e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—EP300—esophageal cancer	5.39e-07	5.54e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.99e-07	4.1e-06	CbGpPWpGaD
